Top 100 US Patents in Drugs
section a - human necessities > medical or veterinary science; hygiene > therapeutic activity of chemical compounds or medicinal preparations
Sorted by IPQ® Score, an objective measure of patent quality. View scores and methodology at PatentRatings.com. You can also view all by publication date instead.
US4775624 (A), filed
Feb 08, 1985
, published
Oct 04, 1988
- LILLY CO ELI
The present invention comprises novel DNA compounds which encode human protein C activity. A variety of eukaryotic and prokaryotic recombinant DNA expression vectors have been constructed that comprise the novel protein C activity-encoding DNA and drive...
US6967201 (B1), filed
May 06, 2002
, published
Nov 22, 2005
- LILLY CO ELI
The present invention provides serotonergic benzofurylpiperazines of Formula I: where: A is a piperazine of formula: and R, RSUP1/SUP, RSUP2/SUP, RSUP3/SUP, RSUP4/SUP, RSUP5/SUP, RSUP5'/SUP, RSUP6/SUP, RSUP6'/SUP, RSUP7/SUP, RSUP7'/SUP, RSUP8/SUP, and...
US5665713 (A), filed
Apr 12, 1995
, published
Sep 09, 1997
- PROCTER GAMBLE
This invention is a pharmaceutical composition that inhibits the growth of cancers and tumors in mammals, particularly in human and warm blooded animals. The composition is also effective against viruses. The composition contains N-phosphonoglycine derivatives...
US5919665 (A), filed
Mar 16, 1995
, published
Jul 06, 1999
- OPHIDIAN PHARM INC
The present invention includes recombinant proteins derived from Clostridium botulinum toxins. In particular, soluble recombinant Clostridium botulinum type A toxin proteins are provided. Methods which allow for the isolation of recombinant proteins free of...
US6060056 (A), filed
Sep 08, 1993
, published
May 09, 2000
- JOLLA PHARMA
Conjugates of nonimmunogenic valency platform molecules and analogs of immunogens that possess the specific B cell binding ability of the immunogen but lack T cell epitopes and which, when introduced into individuals, induce humoral anergy to the immunogen are...
US5902610 (A), filed
Nov 03, 1995
, published
May 11, 1999
- BIONUMERIK PHARMACEUTICALS INC
This invention describes novel formulations containing a water soluble disulfide, 2,2'-dithio-bis-ethane sulfonate, with or without cis-diammine dichloro platinum present in the same formulation, wherein the parenteral or oral administration of 2,2'-dithio-bis...
US7053185 (B1), filed
Aug 15, 2000
, published
May 30, 2006
- HAMLET PHARMA AB
A method for producing an oligomeric form of alpha-lactalbumin which is in the molten globule-like state is described. The method suitably comprises exposing a source of alpha-lactalbumin in which the alpha-lactalbumin is preferably in the molten globule-like...
US5760068 (A), filed
Sep 06, 1996
, published
Jun 02, 1998
- SEARLE CO
PCT No. PCT/US94/12720 Sec. 371 Date Sep. 6, 1996 Sec. 102(e) Date Sep. 6, 1996 PCT Filed Nov. 14, 1994 PCT Pub. No. WO95/15316 PCT Pub. Date Jun. 8, 1995A class of pyrazolyl benzenesulfonamide compounds is described for use in treating inflammation and...
US4386085 (A), filed
Jan 08, 1982
, published
May 31, 1983
- ROUSSEL UCLAF
Novel 19-nor steroids and 19-nor-D-homo-steroids of the formula IMAGE I' wherein R1 is an organic radical of 1 to 18 carbon atoms containing at least one atom selected from the group consisting of nitrogen, phosphorous and silicon with the atom immediately...
US5003080 (A), filed
Feb 01, 1989
, published
Mar 26, 1991
- WARNER LAMBERT CO
US7150870 (B2), filed
Sep 04, 2003
, published
Dec 19, 2006
- COMBI CO
The invention prevents or treats a tumor, inhibiting tumor growth and malignant progression by providing an antitumor agent containing a treated SOD as the active ingredient, especially a melon SOD coated with gliadin. The invention also applies to a method of...
US5750657 (A), filed
Oct 18, 1993
, published
May 12, 1998
- SQUIBB BRISTOL MYERS CO
The subject invention relates to methods and compositions using nondynamic fibrin monomer which is selectively converted to a fibrin polymer which serves as the fibrin sealant.
US4296130 (A), filed
Aug 30, 1979
, published
Oct 20, 1981
- HERSCHLER R J
Preparations containing methylsulfonylmethane (MSM) for administration to the skin, nails, other tissue and/or body fluids of a human or other animal subject are disclosed. Such compositions soften skin, strengthen nails and provide other benefits when applied...
US5985657 (A), filed
Jun 07, 1995
, published
Nov 16, 1999
- NEW ENGLAND MEDICAL CENTER INC
The subject invention concerns a nucleic acid comprising a nucleotide sequence encoding human interleukin-1 (IL-1), and fragments thereof, and the polypeptides and peptides obtained. Specifically, the subject invention comprises the cloning of a cDNA...
US6017536 (A), filed
Dec 20, 1994
, published
Jan 25, 2000
- TRIMERIS INC
The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a simian immunodeficiency virus (SIV) protein. These regions were identified through...
US6667305 (B1), filed
Jan 06, 2003
, published
Dec 23, 2003
- ATHENA NEUROSCIENCES INC
Disclosed are compounds which inhibit beta-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits beta-amyloid peptide...
US6916797 (B2), filed
Aug 30, 2002
, published
Jul 12, 2005
- UCB SA
The invention relates to new alpha-arylethylpiperazine of the formula wherein Z represents 0 or S; n' represents 1 or 2; RSUP2 /SUPrepresents a hydrogen atom or a methyl group; W, ArSUP1 /SUPand ArSUP2 /SUPrepresent various substituents as defined herein; or...
US4665054 (A), filed
Feb 08, 1985
, published
May 12, 1987
- BIOHEAL INC
Derivatives of GHL-Cu possessing greater resistance to proteolytic enzyme breakdown are disclosed. These derivatives can be tailored to increse their fat solubility, making them more useful in the formation of pharmaceutical creams and gels. Further, the...
US4282233 (A), filed
Jun 19, 1980
, published
Aug 04, 1981
- SCHERING CORP
11-(4-Piperidylidene)-5H-benzo-[5,6]-cyclohepta-[1,2-b]-pyridines and their 5,6-dihydro derivatives are disclosed. The compounds are useful as antihistamines with little or no sedative effects.
US4282233 (B1), filed
Jun 19, 1980
, published
Sep 05, 2000
- SCHERING CORP
US5013556 (A), filed
Oct 20, 1989
, published
May 07, 1991
- LIPOSOME TECHNOLOGY INC
A liposome composition which contains between 1-20 mole percent of an amphipathic lipid derivatized with a polyalkylether, as exemplified by phosphatidylethanolamine derivatized with polyethyleneglycol. The derivatized lipid enchances the circulation time of...
US4801600 (A), filed
Oct 09, 1987
, published
Jan 31, 1989
- DU PONT
US6051226 (A), filed
Dec 30, 1993
, published
Apr 18, 2000
- INST OF VIROLOGY SLOVAK ACADEM
A new gene-MN-and proteins/polypeptides encoded therefrom are disclosed. Recombinant nucleic acid molecules for expressing MN proteins/polypeptides and fusion proteins are provided. Expression of the MN gene is disclosed as being associated with tumorigenicity...
US7125559 (B2), filed
Jun 26, 2002
, published
Oct 24, 2006
- OREAL
Cosmetic or dermatological composition characterized in that it comprises a combination of an elastase inhibitor of the N-acylaminoamide family and at least one myorelaxing agent.
US6620835 (B2), filed
Jun 04, 2002
, published
Sep 16, 2003
- WARNER LAMBERT CO
The present invention relates to a method of inhibiting matrix metalloproteinases using compounds that are dibenzofuran sulfonamide derivatives having the Formula IMore particularly, the present invention relates to a method of treating diseases in which...
US6921826 (B2), filed
Oct 29, 2003
, published
Jul 26, 2005
- 3M INNOVATIVE PROPERTIES CO
Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain thioether functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are...
US5281628 (A), filed
Oct 04, 1991
, published
Jan 25, 1994
- AMERICAN CYANAMID CO
9-amino-7-(substituted amino)-6-demethyl-6-deoxytetracyclines having activity against a wide spectrum of organisms including organisms which are resistant to tetracyclines are disclosed. Also disclosed are intermediates and methods for making the novel...
US4827945 (A), filed
Jun 26, 1987
, published
May 09, 1989
- ADVANCED MAGNETICS INC
This invention relates to materials exhibiting certain magnetic and biological properties which make them uniquely suitable for use as magnetic resonance imaging (MRI) agents to enhance MR images of animal organs and tissues. More particularly, the invention...
US4361549 (A), filed
Apr 26, 1979
, published
Nov 30, 1982
- ORTHO PHARMA CORP
Hybrid cell line for production of monoclonal antibody to an antigen found on all normal human T cells and cutaneous T lymphoma cells. The hybrid is formed by fusing splenocytes from immunized CAF1 mice with P3X63Ag8Ul myeloma cells. Diagnostic and therapeutic...
US4409214 (A), filed
Nov 10, 1980
, published
Oct 11, 1983
- FUJISAWA PHARMACEUTICAL CO
US7009036 (B2), filed
Feb 20, 2002
, published
Mar 07, 2006
- PROVINCIA ITALIANA DELLA CONGR
A novel peptide, derived from the human fibroblast growth factor (bFGF), is identified. The molecule is able to inhibit in vitro the effects of Platelet Derived Growth Factor (PDGF-BB) and basic Fibroblast Growth Factor (bFGF) on primary rat smooth muscle...
US4496538 (A), filed
Jul 06, 1982
, published
Jan 29, 1985
- CONNAUGHT LAB
A water-soluble covalent polysaccharide-diphtheria toxoid conjugate having a molecular weight between 140,000 and 4,500,000 dalton and a ribose/protein ratio between 0.25 and 0.75, capable of producing T-cell dependent antibody response to polysaccharide from...
US7053176 (B1), filed
Jul 22, 2002
, published
May 30, 2006
- ALTANA PHARMA AG
Pharmaceutical composition for the treatment of infant respiratory distress syndrome and acute lung injury (including adult respiratory distress syndrome) which contains C1 esterase inhibitor (C1-INH) and lung surfactant which comprises a lung surfactant...
US7101866 (B2), filed
Oct 02, 2001
, published
Sep 05, 2006
- GLAXO GROUP LTD
According to one aspect of the invention, there is provided a compound of formula (I) and solvates thereof. There are also provided compositions containing the compound, processes for preparing it, and its use in therapy.
US7022709 (B2), filed
Jul 23, 2001
, published
Apr 04, 2006
- NIEWOEHNER ULRICH
The invention relates to the use of selective phosphodiesterase 2 (PDE 2) inhibitors for producing pharmaceuticals for improving perception, concentration, learning and/or memory.
US7105550 (B2), filed
Aug 29, 2002
, published
Sep 12, 2006
- KENNIS LUDO EDMOND JOSEPHINE
This invention concerns the use of a compound of formula (I') a N-oxide, pharmaceutically acceptable addition salt, quaternary amine and stereochemically isomeric form thereof, wherein Q is optionally substituted CSUB3-6/SUBcycloalkyl, phenyl, naphthyl,...
US4631286 (A), filed
Oct 25, 1984
, published
Dec 23, 1986
- HOECHST ROUSSEL PHARMA
There are disclosed compounds having the formula IMAGE wherein X is hydrogen, loweralkyl, loweralkoxy, halogen, hydroxy, nitro, NHCOR2 wherein R2 is loweralkyl, or a group of the formula NR3R4 wherein R3 and R4 are independently hydrogen or loweralkyl; R...
US4425341 (A), filed
Mar 14, 1978
, published
Jan 10, 1984
- FUJISAWA PHARMACEUTICAL CO
7-Substituted 3-cephem or cephem compounds characterized by the grouping, in the 7-position thereof, of the formula: R'-A-CONH- where R' is thiadiazolyl or amino thiazolyl, and a is methylene carrying oxyiimino, or R' is haloacetyl and A may also be methylene,...
US4526988 (A), filed
Mar 10, 1983
, published
Jul 02, 1985
- LILLY CO ELI
A 2,2-difluoro-2-desoxycarbohydrate is used to prepare antiviral nucleosides.
US4263428 (A), filed
Feb 23, 1979
, published
Apr 21, 1981
- UNIV CALIFORNIA
A new group of compounds having an enhanced ability to inhibit nucleic acid functions have been prepared. These drugs are bis-anthracyclines wherein two anthracycline molecules are linked through their C-13 carbon atoms by amino and/or hydroxy-dicarboxylic...
US6635632 (B1), filed
Dec 22, 1997
, published
Oct 21, 2003
- ATHENA NEUROSCIENCES INC
Disclosed are compounds which inhibit beta-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits beta-amyloid peptide...
US6756211 (B1), filed
May 11, 1993
, published
Jun 29, 2004
- CORVAS INT INC
Compositions enriched for Neutrophil Inhibitory Factor which inhibit neutrophil activity including adhesion to vascular endothelial cells are provided. Such compositions may comprise a glycoprotein isolated from nematodes. These compositions are useful in the...
US6541485 (B1), filed
Jun 07, 2000
, published
Apr 01, 2003
- 3M INNOVATIVE PROPERTIES CO
Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain urea, thiourea, acylurea, or sulfonylurea functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesi...
US4237161 (A), filed
Aug 07, 1978
, published
Dec 02, 1980
- BEECHAM GROUP LTD
Esters of an acid of formula: IMAGE which is termed "monic acid" have activity against Gram-positive and Gram-negative organisms.
US4753935 (A), filed
Jan 30, 1987
, published
Jun 28, 1988
- SYNTEX INC
US4458076 (A), filed
May 31, 1983
, published
Jul 03, 1984
- HOECHST ROUSSEL PHARMA
Novel 3-(4-piperidinyl)-1,2-benzisothiazoles, processes for the preparation thereof, and method of treating psychoses and alleviating pain employing compounds or compositions thereof are disclosed.
US4287200 (A), filed
Jul 27, 1979
, published
Sep 01, 1981
- TAKEDA CHEMICAL INDUSTRIES LTD
Thiazolidine derivatives of the general formula: IMAGE [wherein R1 is alkyl, cycloalkyl, phenylalkyl, phenyl, a five- or six-membered heterocyclic group including one or two hetero-atoms selected from the group consisting of nitrogen, oxygen and sulfur or a...
US4479932 (A), filed
May 18, 1982
, published
Oct 30, 1984
- UNIV FLORIDA
Centrally acting drug species are site-specifically/sustainedly delivered to the brain by administering to a patient in need of such treatment a therapeutically effective amount of the target drug species [D] tethered to a reduced, blood-brain barrier...
US6683088 (B2), filed
Dec 06, 2001
, published
Jan 27, 2004
- 3M INNOVATIVE PROPERTIES CO
Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain ether and sulfonamide or sulfamide functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of...
US4278793 (A), filed
Jul 21, 1980
, published
Jul 14, 1981
- HOECHST AG
Cephem derivatives of the general formula IMAGE in which the R2O group is in the syn-position, a process for their manufacture and pharmaceutical formulations which are active against bacterial infections and contain these compounds.
US4582865 (A), filed
Dec 06, 1984
, published
Apr 15, 1986
- BIOMATRIX INC
Disclosed are cross-linked gels of hyaluronic acid, alone or mixed with other hydrophilic polymers and containing various substances or covalently bonded low molecular weight substances and processes for preparing them. These products are useful in numerous...
US6664265 (B2), filed
Jun 07, 2002
, published
Dec 16, 2003
- 3M INNOVATIVE PROPERTIES CO
Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain ether and amide functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and...
US6156781 (A), filed
Nov 24, 1999
, published
Dec 05, 2000
- SEARLE CO
A class of pyrazolyl benzenesulfonamide compounds is described for use in treating inflammation and inflammation-related disorders. Compounds of particular interest are defined by Formula II: wherein R2 is selected from hydrido, alkyl, haloalkyl, alkoxycarbony...
US4647773 (A), filed
Apr 23, 1984
, published
Mar 03, 1987
- US HEALTH
A cell system is disclosed for the reproducible detection and isolation of human T-lymphotropic retroviruses (HTLV-family) with cytopathic effects (HTLV-III) from patients with the acquired immune deficiency syndrome (AIDS), pre-AIDS and in healthy carriers....
US6413960 (B1), filed
May 30, 2000
, published
Jul 02, 2002
- SEARLE CO
A class of pyrazolyl benzenesulfonamide compounds is described for use in treating inflammation and inflammation-related disorders. Compounds of particular interest are defined by Formula II:wherein R2 is selected from hydrido, alkyl, haloalkyl, alkoxycarbonyl...
US6492411 (B1), filed
Apr 17, 2002
, published
Dec 10, 2002
- SEARLE CO
A class of pyrazolyl benzenesulfonamide compounds is described for use in treating inflammation and inflammation-related disorders. Compounds of particular interest are defined by Formula II:wherein R2 is selected from hydrido, alkyl, haloalkyl, alkoxycarbonyl...
US4444683 (A), filed
Nov 17, 1982
, published
Apr 24, 1984
- UNIV UTAH
Synthesized succinyl and glutaryl glucosamines, p-(succinylamido)-phenyl- alpha -D-gluco- and mannopyranosides, p-(glutarylamido)-phenyl- alpha -D-gluco- and mannopyranosides and p-(isothiocyanotophenyl)- alpha -D-gluco- and mannopyranosides are reacted with...
US5237110 (A), filed
Feb 16, 1990
, published
Aug 17, 1993
- WISCONSIN ALUMNI RES FOUND
US7030225 (B1), filed
Aug 26, 1999
, published
Apr 18, 2006
- JAPAN TOBACCO INC
A cell surface molecule that is expressed specifically in thymocytes, lymphocytes activated by ConA-stimulation, and peripheral blood lymphocytes. This molecule is involved in signal transmission of the secondary signal (costimulatory signal) essential for the...
US4234588 (A), filed
Feb 07, 1979
, published
Nov 18, 1980
- SMITH KLINE FRENCH LAB
The compounds are substituted pyrimidine compounds which are histamine H2-antagonists. A specific compound of the present invention is 2-[2-(5-dimethylaminomethyl)-2-furylmethylthio)ethylamino]-5-(3-pyridy lmethyl)-4-pyrimidone.
US7115650 (B1), filed
Jan 03, 2002
, published
Oct 03, 2006
- FERRING BV
Inhibitors of dipeptidyl peptidase IV and pharmaceutical compositions comprising these inhibitors are useful in the treatment of infertility, and particularly human female infertility due to polycystic ovary syndrome.
US5149321 (A), filed
Oct 10, 1990
, published
Sep 22, 1992
- KLATZ RONALD M
This invention discloses a method for resuscitating the brain as a result of ischemic and anoxic injuries whereby the patient survives neurologically intact. The method includes the steps of catheterizing the patient's circulatory system and introducing a...
US4746680 (A), filed
Apr 19, 1985
, published
May 24, 1988
- BOOTS CO PLC
Compounds of formula I IMAGE in which R1 is C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 cycloalkyl, cycloalkylalkyl or optionally substituted phenyl; R2 is H or C1-3 alkyl; R3 and/or R4 are H, formyl, C1-3 alkyl, C3-6 alkenyl, C3-6 alkynyl, C3-7...
US5945275 (A), filed
Oct 18, 1994
, published
Aug 31, 1999
- CORVAS INT INC
Proteins which are potent anticoagulants and have at least one NAP domain and are described. These proteins having anticoagulant activity can be isolated from natural sources as nematodes, chemically synthesized or made by recombinant methods using various DNA...
US7232800 (B2), filed
Nov 10, 2003
, published
Jun 19, 2007
- SHANGHAI HUAYI BIOTECH LAB
The present invention provides a Magainin derivative peptide and method of production thereof. Also provided is a pharmaceutically composition comprising said Magainin derivative peptide and pharmaceutically acceptable carrier and/or pharmaceutically...
US5100899 (A), filed
Jun 06, 1989
, published
Mar 31, 1992
- CALNE ROY
US6844443 (B2), filed
Jul 07, 2003
, published
Jan 18, 2005
- TAKEDA PHARMACEUTICAL
A method for producing a compound represented by the formula:wherein the ring A is a benzene ring which may be substituted in addition to the R' group; R1 is hydrogen or an optionally substituted hydrocarbon residue; X is a direct bond or a spacer having an...
US6007988 (A), filed
Jun 02, 1997
, published
Dec 28, 1999
- MEDICAL RES COUNCIL
PCT No. PCT/GB95/01949 Sec. 371 Date Jun. 3, 1997 Sec. 102(e) Date Jun. 3, 1997 PCT Filed Aug. 17, 1995 PCT Pub. No. WO96/06166 PCT Pub. Date Feb. 29, 1996Disclosed are libraries of DNA sequences encoding zinc finger binding motifs for display on a particle,...
US4427690 (A), filed
Sep 24, 1976
, published
Jan 24, 1984
- BEECHAM GROUP LTD
A new antibacterially active agent has been isolated from Streptomyces clavuligerus. This new compound which is designated clavulanic acid has the formula (I): IMAGE (I) In addition to being a broad spectrum antibiotic of medium potency, clavulanic acid...
US7332496 (B2), filed
Apr 21, 2004
, published
Feb 19, 2008
- PARION SCIENCES INC
The present invention relates to a compound represented by formula (I): in which at least one of RSUP3 /SUPand RSUP4 /SUPis a group represented by formula (A): where the structural variables are as defined herein. The compounds are useful for blocking sodium...
US6395474 (B1), filed
Nov 22, 1993
, published
May 28, 2002
A novel class of compounds, known as peptide nucleic acids, bind complementary ssDNA and RNA strands more strongly than a corresponding DNA. The peptide nucleic acids generally comprise ligands such as naturally occurring DNA bases attached to a peptide...
US6683181 (B2), filed
Nov 05, 2002
, published
Jan 27, 2004
- PHARMACIA AND UPJOHN COMAPNY
The present invention provides a compound of formula Iwhich is useful as antiviral agents, in particular, as agents against viruses of the herpes family.
US4708818 (A), filed
Oct 08, 1985
, published
Nov 24, 1987
- US HEALTH
Retroviruses associated with Acquired Immune Deficiency Syndrome (AIDS), including Lymphadenopathy Associated Virus (LAV), are isolated from the sera of patients afflicted with Lymphadenopathy Syndrome (LAS) or AIDS. LAV is a Human Immunodeficiency Virus...
US6087186 (A), filed
Feb 02, 1995
, published
Jul 11, 2000
- IRORI
The present invention provides labeled synthetic libraries of random oligomers and methods and apparatus for generating labeled synthetic oligomer libraries. Each member of such a library is labeled with a unique identifier tag that specifies the structure or...
US5977318 (A), filed
Jun 07, 1995
, published
Nov 02, 1999
- SQUIBB BRISTOL MYERS CO
The invention identifies the CTLA4 receptor as a ligand for the B7 antigen. The complete amino acid sequence encoding human CTLA4 receptor gene is provided. Methods are provided for expressing CTLA4 as an immunoglobulin fusion protein, for preparing hybrid...
US4288434 (A), filed
Mar 14, 1978
, published
Sep 08, 1981
- ROUSSEL UCLAF
Novel syn isomers of 7-amino-thiazolyl-acetamido-3-acetoxymethyl-cephalosporanic acid derivatives of the formula IMAGE I wherein R1 is selected from the group consisting of -CN, -CONH2 and -COOR1', R1' is selected from the group consisting of alkyl of 1...
US4703125 (A), filed
Jul 01, 1986
, published
Oct 27, 1987
- BAYER AG
A carbonyl compound of the formula IMAGE in which R1 denotes hydrogen, aryl, substituted aryl or a straight-chain or cyclic, saturated or unsaturated aliphatic hydrocarbon radical, which is optionally interrupted by O, S, N, N-alkyl, N-aryl or N-aralkyl,...
US5162430 (A), filed
Nov 14, 1989
, published
Nov 10, 1992
- COLLAGEN CORP
Collagen, particularly atelopeptide collagen, exhibits improved handling characteristics when chemically conjugated and/or crosslinked with a synthetic hydrophilic polymer.
US6995241 (B1), filed
Apr 03, 2002
, published
Feb 07, 2006
- MERCK PATENT GMBH
ANIC-BP-1B polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing ANIC-BP-1B polypeptides and polynucleotides in diagnostic assays.
US6608182 (B1), filed
Jun 06, 1995
, published
Aug 19, 2003
- HUMAN GENOME SCIENCES INC
The present invention relates to polypeptides comprising amino acids 85 to 165 of SEQ ID NO:2, as well as polynucleotides which encode these polypeptides. Also provided are methods of treatment using these polypeptides.
US5043345 (A), filed
Aug 31, 1989
, published
Aug 27, 1991
- NOVONORDISK AS
US6696459 (B1), filed
Oct 14, 1997
, published
Feb 24, 2004
- LIGAND PHARM INC
Non-steroidal compounds which are high affinity, high selectivity modulators for steroid receptors are disclosed. Also disclosed are pharmaceutical compositions incorporating such compounds, methods for employing the disclosed compounds and compositions for...
US7067474 (B1), filed
Aug 17, 2000
, published
Jun 27, 2006
- MAX DELBRUECK CENTRUM
The present invention relates to peptides that affect the interaction of the protein beta-catenin with a transcription factor or a tumor suppressor protein. Such peptides are derived either from the amino acids of beta-catenin that are known to interact with...
US6949549 (B2), filed
Jan 16, 2003
, published
Sep 27, 2005
- MERCK SHARP DOHME
A class of substituted imidazolo[5,1-a]phthalazine derivatives as ligands for GABASUBA /SUBreceptors of formula I which are partial or full inverse agonists of an alpha5 receptor subunit while being relatively free of activity at alpha1 and/or alpha2 and/or...
US4447424 (A), filed
Jun 10, 1982
, published
May 08, 1984
- ROUSSEL UCLAF
Novel 19-nor steroids and 19-nor-D-homo-steroids of the formula IMAGE I' wherein R1 is an organic radical of 1 to 18 carbon atoms containing at least one atom selected from the group consisting of nitrogen, phosphorous and silicon with the atom immediately...
US6987131 (B1), filed
Jun 26, 2000
, published
Jan 17, 2006
- BURZYNSKI STANISLAW R
Pharmaceutical compositions are disclosed comprising one or more compounds selected from the group consisting of phenylacetylglutamine, phenylacetylisoglutamine, and phenylacetic acid, in addition to pharmaceutically-acceptable salts, analogs, and precursors...
US4244957 (A), filed
Nov 06, 1978
, published
Jan 13, 1981
- HOFFMANN LA ROCHE
2-Imino-imidazolidine derivatives of the formula IMAGE wherein R1, R2, R3 and R4 are as hereinafter set forth, and pharmaceutically acceptable acid addition salts thereof, are described. The 2-imino-imidazolidine derivatives are useful in the treatment of...
US4337257 (A), filed
May 19, 1980
, published
Jun 29, 1982
- HAESSLE AB
US4758516 (A), filed
Dec 13, 1983
, published
Jul 19, 1988
- FLOREY HOWARD INST
US4522828 (A), filed
Apr 05, 1982
, published
Jun 11, 1985
- BOOTS CO PLC
Compounds of formula I IMAGE in which R1 is C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 cycloalkyl, cycloalkylalkyl or optionally substituted phenyl; R2 is H or C1-3 alkyl; R3 and/or R4 are H, formyl, C1-3 alkyl, C3-6 alkenyl, C3-6 alkynyl, C3-7...
US4461759 (A), filed
Jan 03, 1983
, published
Jul 24, 1984
- VEREX LAB
A constant order release rate solid oral dosage formulation of verapamil or a pharmaceutically acceptable salt thereof, said formulation comprising: a therapeutically effective amount of verapamil; from about 0.5 to 6.0 weight percent of an acid-retardant or...
US6933297 (B2), filed
Sep 08, 2003
, published
Aug 23, 2005
- ASTRAZENECA AB
A compound, 7-chloro-4-hydroxy-2-(2-pyridylethyl)-1,2,5,10-tetrahydropyridazino[4,5-b]quinoline-1,10-dione, its (-) enantiomer, its (+) enantiomer, pharmaceutically-acceptable salts thereof, a method for treating pain comprising administering a pain-ameliorati...
US7335355 (B2), filed
May 28, 2003
, published
Feb 26, 2008
- HANSA MEDICAL AB
A method of identifying an agent that enhances the anti-microbial activity of cationic anti-microbial peptides by blocking the inhibitory effects of the proteinase/glycosaminoglycan pathway, which method comprises: (i) providing, as a first component, a...
US6248781 (B1), filed
Oct 19, 1999
, published
Jun 19, 2001
- NOVO NORDISK AS
The present invention relates to compounds of formula (I)wherein R1, R2, R3, R4, R5, R6, R7, R8, Ar, X, Q, A, Y and Z are as defined in the specification. These compounds are useful in the treatment and/or prevention of conditions mediated by nuclear...
US7402572 (B2), filed
Apr 23, 2004
, published
Jul 22, 2008
- UNIV IOWA RES FOUND
Nucleic acids containing unmethylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response and to redirect a Th2 response to a Th1 response in a subject are disclosed. Methods for treating atopic diseases,...
US5925663 (A), filed
Oct 03, 1997
, published
Jul 20, 1999
- BAYER AG
PCT No. PCT/EP96/01435 Sec. 371 Date Oct. 3, 1997 Sec. 102(e) Date Oct. 3, 1997 PCT Filed Apr. 1, 1996 PCT Pub. No. WO96/32395 PCT Pub. Date Oct. 17, 1996Novel benzimidazole derivatives of the formula R1, R2, X1, X2, X3, X4 and Y are each as defined in the...
US6093743 (A), filed
Jun 23, 1998
, published
Jul 25, 2000
- MEDINOX INC
The present invention provides a novel dithiocarbamate disulfide dimer useful in various therapeutic treatments, either alone or in combination with other active agents. In one method, the disulfide derivative of a dithiocarbamate is coadministered with an...
US6537972 (B1), filed
May 29, 1998
, published
Mar 25, 2003
- SUBSIDIARY NO 3 INC
The present invention relates to the identification of a number of human genes as cellular targets for the design of therapeutic agents for suppressing human immunodeficiency virus infection. These genes encode products which appear to be necessary for HIV...
US4717720 (A), filed
Apr 10, 1986
, published
Jan 05, 1988
- CIRD
A benzonaphthalene compound has the formula IMAGE (I) wherein R1 represents (i) IMAGE or (ii) -CH2OH; R6 represents IMAGE or OR7 wherein R7 represents hydrogen, alkyl having 1-20 carbon atoms, monohydroxyalkyl or polyhydroxyalkyl, r' or r'' represent...
